What are Injectable Alternatives to Statins?

Statins have been the workhorses of cholesterol treatment for decades, and for good reason: they lower LDL cholesterol and have an enormous body of evidence showing that they reduce heart attacks and strokes. But sometimes the relationship between a patient and a statin is less “happily ever after” and more “we need to talk.” Muscle symptoms, medication interactions, inadequate LDL reduction, or genetically high cholesterol can leave people looking for another option.

That is where injectable cholesterol medications enter the picture. The best-known options include the PCSK9 monoclonal antibodies evolocumab (Repatha) and alirocumab (Praluent), along with the longer-acting small interfering RNA drug inclisiran (Leqvio). For people with the rare condition homozygous familial hypercholesterolemia, evinacumab-dgnb (Evkeeza) is another injectable treatment used in specialized care.

These medicines can produce major reductions in low-density lipoprotein cholesterol, better known as LDL or “bad” cholesterol. However, calling them simply “statin replacements” can be misleading. Many people receive an injectable with a statin rather than instead of one. For patients who truly cannot tolerate statins, though, injectable therapies may become an important part of an alternative LDL-lowering strategy.

Research basis:

Why Would Someone Need an Alternative to Statins?

Statins remain foundational therapy for many people at risk of atherosclerotic cardiovascular disease, or ASCVD. Current U.S. guidance generally favors using the maximum statin dose a person can comfortably tolerate before abandoning the drug class altogether.

There are several reasons additional or alternative therapy may nevertheless be appropriate.

• Statin intolerance: A person may experience adverse effects that improve after reducing or stopping a statin and return with rechallenge.
• LDL remains too high: Even a powerful statin may not provide enough LDL reduction in somebody at very high cardiovascular risk.
• Familial hypercholesterolemia: Genetic disorders can produce extremely high LDL levels that often require multiple medications.
• Previous cardiovascular disease: People with a history of heart attack, stroke, or other forms of ASCVD may have aggressive LDL-lowering targets.
• Difficulty maintaining daily medication: A less-frequent injectable regimen may make treatment easier for selected patients.

Importantly, muscle pain while taking a statin does not automatically mean all statins are permanently off the table. Clinicians may investigate other causes, adjust the dose, try another statin, or experiment with less frequent dosing. The National Lipid Association distinguishes between partial statin intolerance, in which some statin therapy can still be tolerated, and complete intolerance.

Translation: before firing every statin in the pharmacy, it is worth confirming which one actually deserves the pink slip.

Research basis:

PCSK9 Inhibitor Injections: The Main Injectable Statin Alternatives

Evolocumab (Repatha)

Evolocumab is a monoclonal antibody targeting a liver-related protein called PCSK9. PCSK9 contributes to the destruction of LDL receptors on liver cells. Those receptors act rather like microscopic cholesterol vacuum cleaners: they pull LDL particles out of the bloodstream.

Block PCSK9, and more LDL receptors survive. More functioning receptors mean more LDL cholesterol can be cleared from circulating blood.

For many adults, Repatha may be given as a subcutaneous injection of 140 mg every two weeks or 420 mg monthly. Specific regimens differ in conditions such as homozygous familial hypercholesterolemia.

PCSK9 monoclonal antibodies frequently lower LDL cholesterol by roughly 50% to 60% or more, depending on the population and background therapy. Evolocumab also has cardiovascular-outcome evidence. In the FOURIER trial program, treatment reduced important cardiovascular events in high-risk patients receiving background lipid-lowering therapy.

The FDA’s current prescribing information includes its use for lowering LDL in adults with hypercholesterolemia and for reducing major cardiovascular events in certain adults at increased cardiovascular risk.

Research basis:

Alirocumab (Praluent)

Alirocumab belongs to the same PCSK9 monoclonal antibody family. It binds circulating PCSK9, helping preserve LDL receptors so the liver can remove more cholesterol from the bloodstream.

Depending on the prescribed regimen and clinical situation, it is administered under the skin at scheduled intervals. Prefilled pens make self-administration possible for many patients after appropriate instruction.

Alirocumab can produce powerful LDL reductions and has cardiovascular-outcome evidence as well. The ODYSSEY OUTCOMES program showed cardiovascular benefits in high-risk patients following acute coronary syndrome. Research involving people with documented statin intolerance has also demonstrated substantially larger LDL reductions with alirocumab than with ezetimibe alone.

That does not mean everybody with an LDL reading slightly above goal should rush toward an injection pen. PCSK9 antibodies tend to be especially valuable when cardiovascular risk is high, LDL reduction needs are substantial, familial hypercholesterolemia is present, or tolerated statin therapy is insufficient.

Research basis:

Inclisiran (Leqvio): A Different Way to Target PCSK9

Inclisiran ultimately targets the same PCSK9 pathway, but it approaches the job differently.

Instead of being an antibody that attaches to PCSK9 already circulating in the body, inclisiran is a small interfering RNA, or siRNA. It works inside liver cells to reduce production of PCSK9 by interfering with the messenger RNA involved in making the protein.

The result is once again more available LDL receptors and lower circulating LDL cholesterol.

One of inclisiran’s standout features is its schedule. According to current U.S. prescribing information, adults receive a 284-mg subcutaneous injection initially, another dose three months later, and then a dose every six months. It is administered by a healthcare professional.

For somebody who has spent years trying to remember a tablet every evening, two maintenance injections per year can sound suspiciously luxurious.

Clinical trials have demonstrated LDL reductions of roughly 40% to 50% in studied populations. However, there is an important evidence distinction between inclisiran and the monoclonal antibodies. The 2026 ACC/AHA dyslipidemia guidance notes that inclisiran continues to be studied to establish whether its LDL lowering translates into fewer cardiovascular events. Evolocumab and alirocumab already have randomized cardiovascular-outcome evidence.

That difference may matter when a clinician chooses among therapies for someone whose primary goal is prevention of another heart attack or stroke.

Research basis:

Evinacumab (Evkeeza): An Injectable Option for Rare Severe Cholesterol Disease

Evinacumab belongs in this discussion, but with a large asterisk beside its name.

It is not a routine injectable substitute for statins. Evkeeza targets angiopoietin-like protein 3, or ANGPTL3, and is intended for people with homozygous familial hypercholesterolemia (HoFH), an exceptionally severe inherited cholesterol disorder.

Unlike Repatha, Praluent, and Leqvio, which are given subcutaneously, evinacumab is administered by intravenous infusion. Current FDA labeling uses a weight-based dose given every four weeks as an adjunct to other LDL-lowering treatment for HoFH.

Because HoFH can produce LDL levels several times higher than normal from childhood onward, patients commonly require combination treatment managed by lipid specialists. Evinacumab can lower LDL even through pathways that do not depend entirely on normal LDL-receptor function, which makes it particularly useful in this unusual genetic disease.

Research basis:

How Much Can Injectable Cholesterol Drugs Lower LDL?

The exact response varies, but injectable therapy can be dramatically stronger than many older nonstatin options.

These percentages should be treated as useful reference points rather than promises. Baseline LDL, genetics, other medications, adherence, and the underlying condition can all change the response.

Do Injectable Alternatives Prevent Heart Attacks and Strokes?

This is where discussing LDL numbers alone is not enough.

Evolocumab and alirocumab have cardiovascular-outcome evidence showing that PCSK9 monoclonal antibody therapy can reduce major cardiovascular events in appropriately selected high-risk populations. The 2026 American Diabetes Association Standards of Care summarize evidence showing roughly 15% to 20% reductions in major adverse cardiovascular events in the FOURIER and ODYSSEY OUTCOMES programs when these agents were used in high-risk patients on background treatment.

Inclisiran clearly lowers LDL, but current U.S. cardiovascular guidelines still distinguish LDL-lowering evidence from completed cardiovascular-outcomes evidence. Its outcome trials remain important for determining whether its convenient twice-yearly maintenance schedule delivers the same demonstrated event-reduction benefits.

Evinacumab is a specialist drug for HoFH, and the FDA has noted that its effect on cardiovascular morbidity and mortality has not been established.

Research basis:

What Are the Side Effects?

One reason injectable therapies appeal to people with statin-associated muscle symptoms is that they work through different biological pathways.

Common issues with injectable PCSK9-directed therapy may include:

• Redness, tenderness, itching, bruising, or swelling around the injection site
• Cold-like or upper respiratory symptoms
• Back or muscle discomfort with some products
• Joint pain
• Flu-like symptoms

Serious allergic reactions are uncommon but possible. Product-specific contraindications, pregnancy considerations, drug administration instructions, and other precautions should always be reviewed with a healthcare professional.

Most importantly, someone experiencing muscle symptoms on a statin should not simply stop cardiovascular medication and order a new treatment plan from Dr. Internet University. The cause of symptoms, cardiovascular risk, LDL level, medical history, and insurance coverage all affect the best strategy.

Are Injections Better Than Statins?

Not automatically.

A potent PCSK9 inhibitor may lower LDL more dramatically than a moderate-intensity statin, but “which drug lowers the laboratory number more?” is not the only question that matters.

Statins are inexpensive, widely available, easy to take, extensively studied, and supported by decades of cardiovascular-outcome data. That is why U.S. guidelines continue to place them at the center of LDL-lowering therapy when they are tolerated.

Injectables become especially attractive when a person:

• Cannot tolerate an adequate statin dose
• Has already developed ASCVD and remains above an LDL goal
• Needs a very large additional reduction in LDL
• Has familial hypercholesterolemia
• Has difficulty adhering to daily medication
• Needs combination therapy because one medication is not enough

Sometimes the best treatment is not “statin versus injection” at all. It may be a low or moderate statin dose combined with ezetimibe, a PCSK9 inhibitor, or another nonstatin therapy.

What About Oral Alternatives?

Needles are not the only escape route from statins. Nonstatin oral medications include ezetimibe and bempedoic acid, among others.

There is also a very recent development worth knowing about. In July 2026, the FDA approved enlicitide (Lipfendra), the first oral PCSK9 inhibitor for adults with hypercholesterolemia. Therefore, the phrase “PCSK9 inhibitor” no longer automatically means “injection.”

Which approach makes sense depends on cardiovascular risk, the amount of additional LDL lowering required, previous medications, convenience, cost, insurance requirements, and the strength of outcome evidence for the patient’s situation.

Research basis:

What the Injectable Treatment Experience Can Be Like

Reading that a medication can cut LDL by 50% is useful. Knowing what treatment may feel like on an ordinary Tuesday is useful in a completely different way.

Experience 1: Discovering That “Statin Intolerant” Is Not Always All-or-Nothing

Imagine a patient who has tried atorvastatin twice and developed aching thighs each time. The understandable first reaction might be, “That settles it. My body hates statins.”

In practice, a clinician may investigate thyroid problems, medication interactions, exercise-related soreness, vitamin deficiencies, or other contributors. Another statin may be tried at a lower dose or with an intermittent schedule. Some patients discover that they can tolerate a small amount of statin therapy after all.

If LDL remains far above target despite the maximum tolerated regimen, an injectable may then be added. The experience becomes less about replacing one medicine with another and more about constructing a personalized cholesterol-lowering toolbox.

Experience 2: The First Self-Injection Is Usually the Weirdest One

For somebody prescribed a PCSK9 monoclonal antibody, the first psychological hurdle may have nothing whatsoever to do with cholesterol. It may simply be: “You expect me to stick that in myself?”

Prefilled injection devices are designed to simplify administration, and patients are typically taught how and where to inject the medication. After the first few doses, the procedure can become routineremove the medication as instructed, prepare the injection site, use the device correctly, dispose of it safely, and continue with the day.

Some people notice temporary redness or tenderness afterward. Others barely think about the injection once it is finished. A dosing reminder on a phone or calendar can help prevent an every-two-week or monthly treatment from turning into “Wait, was that supposed to be yesterday?”

Experience 3: Twice-Yearly Dosing Changes the Routine

Inclisiran provides a substantially different experience because a healthcare professional administers it. After the initial dose and three-month dose, maintenance treatment occurs every six months.

That can eliminate the need to store injection pens at home or remember frequent self-injections. For people who struggle with medication adherence, the clinic-based schedule may be appealing.

The tradeoff is obvious: treatment requires appointments. Somebody who travels frequently or has limited access to medical care may prefer a self-administered option even if injections are more frequent.

Experience 4: The LDL Test Can Be the Most Satisfying Part

For someone who has battled genetically high LDL for years, the follow-up laboratory result can be dramatic. A substantial reduction may provide reassurance that the new strategy is biologically doing exactly what it was supposed to do.

That does not mean treatment is finished. Cholesterol management is generally long term, particularly in people with established cardiovascular disease or familial hypercholesterolemia. Stopping an effective medication can allow LDL to rise again.

Experience 5: Insurance Can Become Part of the Treatment Story

The prescription itself may be only one step. Depending on insurance coverage and the indication, patients may encounter prior authorization requirements or requests documenting previous cholesterol treatments.

This is one practical reason keeping a clear medication history can help. Knowing which statins were tried, the doses used, what symptoms occurred, previous LDL measurements, and which other treatments failed to reach the desired goal may make conversations among the patient, clinician, pharmacy, and insurer considerably easier.

The overall lesson from real-world treatment is surprisingly ordinary: the “best” injectable is not simply whichever medication produces the biggest percentage in a clinical trial. A treatment also has to fit the person’s cardiovascular risk, biology, tolerance, schedule, access, and willingness to stay with it for years.

Conclusion: Injectable Statin Alternatives Are Powerful, but Selection Matters

For people who need substantial LDL lowering beyond what statins can provideor who cannot tolerate an adequate statin regimenmodern injectable therapies have dramatically expanded the options.

Evolocumab and alirocumab are PCSK9 monoclonal antibodies capable of major LDL reductions and backed by cardiovascular-outcome evidence in high-risk populations. Inclisiran attacks the PCSK9 pathway using RNA interference and stands out for maintenance dosing only twice per year, although cardiovascular-outcome evidence is still being developed. Evinacumab serves a much narrower role in people with homozygous familial hypercholesterolemia.

None of these treatments makes lifestyle habits irrelevant, and none should prompt someone to discontinue a statin without medical guidance. Instead, they give clinicians more ways to match LDL-lowering intensity to an individual’s cardiovascular risk.

And that may be the biggest improvement of all: cholesterol treatment no longer has to be a choice between “take this statin” and “good luck.” There are now several different biological pathways, dosing schedules, and medication combinations available to help bring stubborn LDL under control.

Medical note: This article is for educational purposes and does not replace individualized medical advice. Prescription cholesterol therapy should be selected with a qualified healthcare professional based on LDL levels, cardiovascular risk, medical history, other medications, and treatment tolerance.